BNTX BioNTech SE

Summit Therapeutics (SMMT) shares rose early Tuesday after British drugmaker AstraZeneca (AZN) agree

In mid-September 2026, Pfizer Canada and BioNTech announced Health Canada’s approval of the Omicron XFG‑adapted COMIRNATY vaccine for individuals aged 6 months and older, aligning with 2026–2027 public health recommendations. A few days earlier, BioNTech and OncoC4 reported that investigational CTLA‑4 antibody gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial stage, underscoring BioNTech’s expanding presence in late‑stage oncology. We’ll...

European equities traded in the US as American depositary receipts were tracking modestly higher lat

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with […]

Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.

European equities traded in the US as American depositary receipts Tuesday were tracking lower Tuesd

Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.

Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is moving markets and what it signals about what that dataset might show.

European equities traded in the US as American depositary receipts started the week higher on Monday

European equities traded in the US as American depositary receipts were heading lower late Friday mo

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index adding 0.8% and the S

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.

BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether today’s valuation rests on a solid revenue base or on expectations that are hard to pin down. Over the past 5 years the share price has fallen 71.5%, which puts the spotlight firmly on whether the current...

BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. This suggests that...

European equities traded in the US as American depositary receipts were heading lower late Tuesday m

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the […]

On Monday, BioNTech SE (NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific patient population. Following the announcement, the stock jumped nearly 2%. Evaluating Gotistobart for Lung Cancer The study investigates gotistobart (BNT316 or ONC-392) for metastatic squamous non-small cell lun

Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.

European equities traded in the US as American depositary receipts were trending lower late Thursday

European equities traded in the US as American depositary receipts were tracking lower late Tuesday

Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.

BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was unlikely to demonstrate effectiveness. The decision is more concerning than a routine trial disappointment because the committee identified a numerical imbalance in overall survival between the study groups. […]

European equities traded in the US as American depositary receipts were marginally higher late Frida

GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.

Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.

BioNTech (NasdaqGS:BNTX) halted a Phase 2 trial of its individualized mRNA immunotherapy in colorectal cancer after an independent Data Safety Monitoring Board recommended termination for futility. The board cited a numerical imbalance in overall survival between treatment arms as a key factor in its decision. The discontinued study involved BioNTech's collaboration with Genentech and targeted colorectal cancer, an area described as having significant unmet medical need. This is the first...

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Str

One colorectal failure does not destroy the platform, but it exposes how brutally tumor biology can defeat elegant technology.

BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H

All three major US stock indexes were up in late-morning trading Friday, as market participants pars

European equities traded in the US as American depositary receipts were marginally higher late Frida

BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA technology can actually reach into solid tumors.

BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to treat colorectal cancer.

Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior. The selloff was triggered by the company’s announcement that it has terminated a Phase 2 trial for its mRNA cancer vaccine in colorectal cancer due to futility—a stark reality check for investors hoping the mRNA oncology revolution would be a rising tide that lifts all boats. The timing of the setback could not be more vi

BioNTech SE (NASDAQ:BNTX) rallied following the first positive interim Phase 3 topline result for a personalized mRNA cancer therapy. Moderna and Merck said intismeran, combined with Keytruda, significantly improved recurrence-free and distant metastasis-free survival in patients with surgically removed high-risk melanoma. The result lifted other mRNA developers because it provided the strongest evidence yet that […]

European equities traded in the US as American depositary receipts were trending lower late Thursday

Moderna stock shed 7% on Wednesday with no company news to blame, reopening a brutal question that its 439% year-to-date rally had been drowning out: what exactly does a $59 billion valuation buy on a revenue base this thin?

Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the entire post-KEYTRUDA story.

Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector. Something broke between these two names, and figuring out what it means for your position is more urgent than it looks.

Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk.

Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or the beginning of a painful unwind for latecomers.

European equities traded in the US as American depositary receipts started the week slightly lower l

BioNTech SE has already presented new clinical data from its broad lung cancer pipeline at the 2026 IASLC World Conference on Lung Cancer in Seoul, covering key assets pumitamig, gotistobart and several mRNA-based immunotherapy approaches. The company’s first-in-class combination data pairing its PD-(L)1 x VEGF bispecific antibody pumitamig with a B7H3-targeted antibody-drug conjugate underscores BioNTech’s push into differentiated, novel-novel immunotherapy regimens in lung cancer. We’ll...

BioNTech stock has rebounded over the past year but still carries a long term loss for holders, and the current valuation checks lean more expensive than cheap. After a strong share price recovery in recent weeks, investors are weighing whether the recent momentum is backed up by value or mainly by renewed optimism. BioNTech shareholders have seen the stock decline 67.2% over the last 5 years, which sets a cautious backdrop for judging any fresh rally. Progress in the lung cancer pipeline,...

BioNTech (BNTX) is back in focus after presenting new clinical data from its lung cancer program at the IASLC 2026 World Conference on Lung Cancer in Seoul, highlighting key assets pumitamig and gotistobart. See our latest analysis for BioNTech. BioNTech’s clinical updates arrive alongside strong recent momentum. The share price has delivered a 7 day return of 25.22% and a 90 day share price return of 26.51%, while the 5 year total shareholder return has declined 67.17%, showing how sentiment...

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers

European equities traded in the US as American depositary receipts were trending higher late Friday

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.